Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 4/20 | 0.32 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.31 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16005255 | 0.85 | SCN9A (0.33) | SCN9A | |
| SCHEMBL19664938 | 0.81 | CA12 (0.34) | CA12CA1CA2CA9ALB | |
| SCHEMBL16005162 | 0.79 | MAPT (0.45) | CA12CA1CA2CA9ALB | |
| SCHEMBL16005627 | 0.78 | OPRK1 (0.36) | SCN9ACXCR3 | |
| SCHEMBL16005363 | 0.78 | CA12 (0.35) | CA12CA1CA2CA9ALB | |
| SCHEMBL16005097 | 0.78 | MAPT (0.35) | SCN9A | |
| SCHEMBL16005351 | 0.76 | MAPT (0.39) | CA12CA1CA2CA9ALB | |
| SCHEMBL16005062 | 0.76 | MEN1 (0.35) | SCN9A | |
| SCHEMBL16005092 | 0.76 | MAPT (0.49) | CA12CA1CA2CA9ALB | |
| SCHEMBL16005430 | 0.75 | MAPT (0.40) | CA12CA1CA2CA9ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303248-A1 | N-BENZYLANILINE DERIVATIVE AND USES THEREOF | Neurodawn Pharmaceutical Co., Ltd. (CN) | 2014-10-09 | — | — | US | claimed |
| EP-2774914-B1 | N-BENZYLANILINE DERIVATIVE AND USES THEREOF | UNIV NANJING MEDICAL (CN) | 2017-12-06 | — | — | EP | disclosed |
| US-9481636-B2 | N-benzylaniline derivative and uses thereof | NANJING MEDICAL UNIVERSITY (CN) | 2016-11-01 | — | — | US | disclosed |
| US-20140303248-A1 | N-BENZYLANILINE DERIVATIVE AND USES THEREOF | Neurodawn Pharmaceutical Co., Ltd. (CN) | 2014-10-09 | — | — | US | disclosed |
| EP-2774914-A1 | N-BENZYLANILINE DERIVATIVE AND USES THEREOF | Nanjing Medical University (CN) | 2014-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303248-A1 | N-BENZYLANILINE DERIVATIVE AND USES THEREOF | NLN, INA, TRPV1 | CA12 3914/4885CA1 1325/4885CA2 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.